Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Purdue Pharma Lp Drug Patent Portfolio

Purdue Pharma Lp owns 8 orange book drugs protected by 128 US patents with Chirocaine having the least patent protection, holding only 1 patent. And Hysingla Er with maximum patent protection, holding 42 patents. Given below is the list of Purdue Pharma Lp's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11857547 Compositions and methods for opioid antagonist delivery 05 Nov, 2039
Active
US11865112 Compositions and methods for opioid antagonist delivery 05 Nov, 2039
Active
US10722473 Methods and compositions particularly for treatment of attention deficit disorder 19 Nov, 2038
Active
US10111839 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10292938 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10292939 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10449159 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10500162 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10507186 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10512612 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10512613 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10568841 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US10688060 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US9974752 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
Active
US11191908 Syringe shock absorber for use in an injection device 18 Oct, 2035
Active
US11813435 Needle assisted injection device having reduced trigger force 25 Feb, 2035
Active
US10881798 Needle assisted injection device having reduced trigger force 11 Feb, 2034
Active
US8808740 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
Active
US9572779 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
Active
US9750703 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
Active
US9861584 Tamper resistant controlled release dosage forms 21 Dec, 2031
Active
US9872837 Tamper resistant controlled release dosage forms 21 Dec, 2031
Active
US11185642 Injection device with cammed ram assembly 28 Aug, 2031
Active
US10357609 Needle assisted jet injection device having reduced trigger force 21 Aug, 2031
Active
US10905827 Injection device with cammed ram assembly 21 Aug, 2031
Active
US11446440 Needle assisted injection device having reduced trigger force 21 Aug, 2031
Active
US8496619 Injection device with cammed ram assembly 21 Aug, 2031
Active
US9364610 Injection device with cammed ram assembly 21 Aug, 2031
Active
US9364611 Needle assisted jet injection device having reduced trigger force 21 Aug, 2031
Active
US9446195 Injection device with cammed ram assembly 21 Aug, 2031
Active
US10279131 Injection device with cammed RAM assembly 31 Jul, 2031
Active
US8894987 Tamper resistant dosage forms 29 Mar, 2030
Active
US11304908 Tamper resistant dosage forms 24 Aug, 2027
Active
US11304909 Tamper resistant dosage forms 24 Aug, 2027
Active
US9084816 Tamper resistant dosage forms 24 Aug, 2027
Active
US9095614 Tamper resistant dosage forms 24 Aug, 2027
Active
US9095615 Tamper resistant dosage forms 24 Aug, 2027
Active
US9486412 Tamper resistant dosage forms 24 Aug, 2027
Active
US9486413 Tamper resistant dosage forms 24 Aug, 2027
Active
US9492389 Tamper resistant dosage forms 24 Aug, 2027
Active
US9492390 Tamper resistant dosage forms 24 Aug, 2027
Active
US9492391 Tamper resistant dosage forms 24 Aug, 2027
Active
US9545380 Tamper resistant dosage forms 24 Aug, 2027
Active
US9763933 Tamper resistant dosage forms 24 Aug, 2027
Active
US9770416 Tamper resistant dosage forms 24 Aug, 2027
Active
US9775809 Tamper resistant dosage forms 24 Aug, 2027
Active
US11964056 Tamper resistant dosage forms 24 Aug, 2027
Active
US8808741 Tamper resistant dosage forms 24 Aug, 2027
Active
US8894988 Tamper resistant dosage forms 24 Aug, 2027
Active
US9492392 Tamper resistant dosage forms 24 Aug, 2027
Active
US9492393 Tamper resistant dosage forms 24 Aug, 2027
Active
US9775808 Tamper resistant dosage forms 24 Aug, 2027
Active
US8021335 Prefilled syringe jet injector 04 Oct, 2026
Active
US10478560 Prefilled syringe injector 24 Jan, 2026
Active
US11446441 Prefilled syringe injector 24 Jan, 2026
Active
US8562564 Prefilled syringe jet injector 24 Jan, 2026
Active
US9180259 Prefilled syringe jet injector 24 Jan, 2026
Active
US9533102 Prefilled syringe jet injector 24 Jan, 2026
Active
US9629959 Prefilled syringe jet injector 24 Jan, 2026
Active
US7776314 Abuse-proofed dosage system 19 Apr, 2025
Active
US10407434 Process for preparing oxycodone compositions 30 Mar, 2025
Active
US10696684 Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
Active
US12060361 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
Active
US7674799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
Active
US7674800 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
Active
US7683072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
Active
US9073933 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
Active
US9522919 Oxycodone compositions 30 Mar, 2025
Active
US11844865 Abuse-proofed oral dosage form 13 Feb, 2025
Active
US8114383 Abuse-proofed dosage form 10 Oct, 2024 Expired
US10130591 Abuse-proofed dosage form 20 Nov, 2023 Expired
US8309060 Abuse-proofed dosage form 20 Nov, 2023 Expired
US10675278 Crush resistant delayed-release dosage forms 20 Nov, 2023 Expired
US10369109 Abuse-proofed dosage form 16 Jun, 2023 Expired
US9675610 Abuse-proofed dosage form 16 Jun, 2023 Expired
US8846090 Matrix for sustained, invariant and independent release of active compounds 04 Apr, 2023 Expired
US8846091 Matrix for sustained, invariant and independent release of active compounds 04 Apr, 2023 Expired
US9555000 Pharmaceutical preparation containing oxycodone and naloxone 04 Apr, 2023 Expired
US9907793 Pharmaceutical preparation containing oxycodone and naloxone 04 Apr, 2023 Expired
US8529948 Pharmaceutical formulation containing gelling agent 06 Aug, 2022 Expired
US8337888 Pharmaceutical formulation containing gelling agent 06 Aug, 2022 Expired
US9060976 Pharmaceutical formulation containing gelling agent 06 Aug, 2022 Expired
US8969369 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9056051 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9084729 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9161937 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9168252 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9283216 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9283221 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9345701 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US9511066 Abuse-resistant controlled-release opioid dosage form 10 May, 2022 Expired
US6733783 Controlled release hydrocodone formulations 30 Oct, 2021 Expired
US8361499 Controlled release hydrocodone formulations 30 Oct, 2021 Expired
US8551520 Controlled release hydrocodone 30 Oct, 2021 Expired
US8647667 Controlled release hydrocodone formulations 30 Oct, 2021 Expired
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020 Expired
US9023401 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9056052 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9060940 Controlled release hydrocodone 30 Oct, 2020 Expired
US9198863 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9205056 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9289391 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9517236 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9572804 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9669023 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9669024 Controlled release hydrocodone formulations 30 Oct, 2020 Expired
US9675611 Methods of providing analgesia 30 Oct, 2020 Expired
US9682077 Methods of providing analgesia 30 Oct, 2020 Expired
US6277384 Opioid agonist/antagonist combinations 22 Dec, 2018 Expired
US6696066 Opioid agonist/antagonist combinations 22 Dec, 2018 Expired
US8673355 Opioid agonist/antagonist combinations 22 Dec, 2018 Expired
US8822487 Opioid agonist/opioid antagonist/acetaminophen combinations 22 Dec, 2018 Expired
US9205082 Opioid agonist/antagonist combinations 22 Dec, 2018 Expired
US9474750 Opioid agonist/opioid antagonist/acetaminophen combinations 22 Dec, 2018 Expired
US9642850 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017 Expired
USRE41408 Method of providing sustained analgesia with buprenorpine 29 Sep, 2017 Expired
USRE41489 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017 Expired
USRE41571 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017 Expired
US6488963 Hot-melt extrudable pharmaceutical formulation 24 Jun, 2017 Expired
US6264980 Transdermal resorption of active substances from supercooled masses of levulic acid 18 Dec, 2015 Expired
US6344211 Transdermal absorption of active substances from subcooled melts 18 Dec, 2015 Expired
US5958452 Extruded orally administrable opioid formulations 04 Nov, 2014 Expired
US5965161 Extruded multi-particulates 04 Nov, 2014 Expired
US6335033 Melt-extrusion multiparticulates 04 Nov, 2014 Expired
US6706281 Melt-extrusion multiparticulates 04 Nov, 2014 Expired
US6743442 Melt-extruded orally administrable opioid formulations 04 Nov, 2014 Expired
US5708011 Use of levobupivacaine in a patient having depressed myocardial contractility 13 Oct, 2014 Expired
US5508042 Controlled release oxycodone compositions 16 Apr, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Purdue Pharma Lp.

Activity Date Patent Number
Patent litigations
Expire Patent
Critical
15 Jul, 2024 US10675278
Maintenance Fee Reminder Mailed
Critical
01 Jul, 2024 US8309060
Expire Patent
Critical
01 Jul, 2024 US9345701
Maintenance Fee Reminder Mailed
Critical
01 Jul, 2024 US8309060
Payment of Maintenance Fee, 8th Year, Large Entity 20 Jun, 2024 US9545380
Electronic Review
Critical
07 Jun, 2024 US11964056
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9522919 (Litigated)
Expire Patent
Critical
29 Apr, 2024 US9289391
Patent eGrant Notification 23 Apr, 2024 US11964056
Mail Patent eGrant Notification 23 Apr, 2024 US11964056
Recordation of Patent eGrant 23 Apr, 2024 US11964056
Recordation of Patent Grant Mailed
Critical
23 Apr, 2024 US11964056
Email Notification
Critical
23 Apr, 2024 US11964056
Patent Issue Date Used in PTA Calculation
Critical
23 Apr, 2024 US11964056
Expire Patent
Critical
22 Apr, 2024 US9283221


Purdue Pharma Lp's Drug Patent Litigations

Purdue Pharma Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 11, 2016, against patent number US9060976. The petitioner Amneal Pharmaceuticals, LLC, challenged the validity of this patent, with PURDUE PHARMA L.P. as the respondent. Click below to track the latest information on how companies are challenging Purdue Pharma Lp's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9492392 February, 2018 Terminated-Settled
(21 Aug, 2018)
Purdue Pharma L.P. Kashiv Pharma, LLC
US9492393 February, 2018 Terminated-Settled
(21 Aug, 2018)
Purdue Pharma L.P. Kashiv Pharma, LLC
US9060976 May, 2016 FWD Entered
(08 Nov, 2017)
PURDUE PHARMA L.P. Amneal Pharmaceuticals, LLC


Purdue Pharma Lp Drug Patents' Oppositions Filed in EPO

Purdue Pharma Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19150366A Sep, 2022 Bandpay & Greuter Granted and Under Opposition
EP06719329A Oct, 2019 Bandpay & Greuter Patent maintained as amended
EP11177516A Feb, 2018 Zentiva, k.s. Revoked
EP11177518A Feb, 2018 Zentiva, k.s. Revoked
EP11177518A Feb, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP11177516A Feb, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP11177516A Feb, 2018 Intas Pharmaceuticals Ltd. Revoked
EP11177518A Feb, 2018 Intas Pharmaceuticals Ltd. Revoked
EP11177516A Jan, 2018 STADA Arzneimittel AG Revoked
EP11177518A Jan, 2018 STADA Arzneimittel AG Revoked
EP06706682A Dec, 2017 G. L. Pharma GmbH Revoked
EP11177516A Nov, 2017 G. L. Pharma GmbH Revoked
EP11177518A Nov, 2017 G. L. Pharma GmbH Revoked
EP11177516A Nov, 2017 Ethypharm Revoked
EP11177518A Nov, 2017 Ethypharm Revoked
EP11177520A Aug, 2017 Ethypharm Revoked
EP11177520A Aug, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP11177520A Aug, 2017 Intas Pharmaceuticals Ltd. Revoked
EP11177520A Aug, 2017 G. L. Pharma GmbH Revoked
EP11177518A Jul, 2017 Acino Pharma AG Revoked
EP11177516A Jul, 2017 Acino Pharma AG Revoked
EP11177520A Jun, 2017 STADA Arzneimittel AG Revoked
EP11177516A Jun, 2017 KRKA, d.d., Novo mesto Revoked
EP11177518A Jun, 2017 Krka, d.d., Novo mesto Revoked
EP11177520A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177516A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177518A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177518A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177518A May, 2017 Develco Pharma Schweiz AG Revoked
EP11177516A May, 2017 Develco Pharma Schweiz AG Revoked
EP11177516A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177520A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177520A Apr, 2017 Acino Supply AG Revoked
EP11177520A Apr, 2017 KRKA, d.d., Novo mesto Revoked
EP11177520A Mar, 2017 Develco Pharma Schweiz AG Revoked
EP11186168A Oct, 2016 James Poole Limited Opposition rejected
EP03720424A Mar, 2016 KRKA, d.d., Novo mesto Revoked
EP03720424A Mar, 2016 FRKelly Revoked
EP03720424A Mar, 2016 Zentiva k.s. Revoked
EP03720424A Mar, 2016 Develco Pharma Schweiz AG Revoked
EP03720424A Mar, 2016 STADA Arzneimittel AG Revoked
EP03720424A Mar, 2016 G. L. Pharma GmbH Revoked
EP03720424A Mar, 2016 Hexal AG / Sandoz International GmbH Revoked
EP03720424A Mar, 2016 ETHYPHARM Revoked
EP03720424A Feb, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP03720424A Feb, 2016 Acino Pharma AG Revoked
EP03720424A Dec, 2015 Actavis Group PTC ehf Revoked
EP10011792A Oct, 2015 Setna, Rohan P. Granted and Under Opposition
EP10011792A Oct, 2015 Hoffmann Eitle Granted and Under Opposition
EP10011792A Oct, 2015 James Poole Limited Granted and Under Opposition
EP10011792A Oct, 2015 Acino Pharma AG Granted and Under Opposition
EP05730345A Dec, 2011 Actavis group PTC ehf Patent maintained as amended
EP05730345A Dec, 2011 Acino Pharma AG Patent maintained as amended
EP05730345A Dec, 2011 Elend, Almut Susanne Patent maintained as amended
EP2005006983W Oct, 2009 Sanofi-Aventis Deutschland GmbH Patent maintained as amended
EP2005006983W Oct, 2009 Ypsomed AG Patent maintained as amended
EP03720425A Sep, 2009 Hexal AG Patent maintained as amended
EP04763833A Mar, 2008 Purdue Pharma LP Opposition rejected
EP04763834A Dec, 2007 Purdue Pharma LP Opposition rejected


Purdue Pharma Lp's Family Patents

Purdue Pharma Lp drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 27.2% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Purdue Pharma Lp Drug List

Given below is the complete list of Purdue Pharma Lp's drugs and the patents protecting them.


1. Adhansia Xr

Adhansia Xr is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10722473 Methods and compositions particularly for treatment of attention deficit disorder 19 Nov, 2038
(14 years from now)
Active
US10111839 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10292938 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10292939 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10449159 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10500162 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10507186 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10512612 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10512613 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10568841 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US10688060 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active
US9974752 Methods and compositions particularly for treatment of attention deficit disorder 30 Oct, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adhansia Xr's drug page


2. Butrans

Butrans is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9642850 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017
(7 years ago)
Expired
USRE41408 Method of providing sustained analgesia with buprenorpine 29 Sep, 2017
(7 years ago)
Expired
USRE41489 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017
(7 years ago)
Expired
USRE41571 Method of providing sustained analgesia with buprenorphine 29 Sep, 2017
(7 years ago)
Expired
US6264980 Transdermal resorption of active substances from supercooled masses of levulic acid 18 Dec, 2015
(8 years ago)
Expired
US6344211 Transdermal absorption of active substances from subcooled melts 18 Dec, 2015
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Butrans's drug page


3. Chirocaine

Chirocaine is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5708011 Use of levobupivacaine in a patient having depressed myocardial contractility 13 Oct, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chirocaine's drug page


4. Hysingla Er

Hysingla Er is protected by 42 patents, out of which 22 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8808740 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
(7 years from now)
Active
US9572779 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
(7 years from now)
Active
US9750703 Encased tamper resistant controlled release dosage forms 21 Dec, 2031
(7 years from now)
Active
US9861584 Tamper resistant controlled release dosage forms 21 Dec, 2031
(7 years from now)
Active
US9872837 Tamper resistant controlled release dosage forms 21 Dec, 2031
(7 years from now)
Active
US11304908 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US11304909 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9084816 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9095614 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9095615 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9486412 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9486413 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492389 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492390 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492391 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9545380 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9763933 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9770416 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9775809 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US11844865 Abuse-proofed oral dosage form 13 Feb, 2025
(2 months from now)
Active
US10130591 Abuse-proofed dosage form 20 Nov, 2023
(1 year, 2 days ago)
Expired
US8309060 Abuse-proofed dosage form 20 Nov, 2023
(1 year, 2 days ago)
Expired
US10369109 Abuse-proofed dosage form 16 Jun, 2023
(1 year, 5 months ago)
Expired
US9675610 Abuse-proofed dosage form 16 Jun, 2023
(1 year, 5 months ago)
Expired
US8529948 Pharmaceutical formulation containing gelling agent 06 Aug, 2022
(2 years ago)
Expired
US6733783 Controlled release hydrocodone formulations 30 Oct, 2021
(3 years ago)
Expired
US8361499 Controlled release hydrocodone formulations 30 Oct, 2021
(3 years ago)
Expired
US8551520 Controlled release hydrocodone 30 Oct, 2021
(3 years ago)
Expired
US8647667 Controlled release hydrocodone formulations 30 Oct, 2021
(3 years ago)
Expired
US9023401 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9056052 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9060940 Controlled release hydrocodone 30 Oct, 2020
(4 years ago)
Expired
US9198863 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9205056 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9289391 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9517236 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9572804 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9669023 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9669024 Controlled release hydrocodone formulations 30 Oct, 2020
(4 years ago)
Expired
US9675611 Methods of providing analgesia 30 Oct, 2020
(4 years ago)
Expired
US9682077 Methods of providing analgesia 30 Oct, 2020
(4 years ago)
Expired
US6488963 Hot-melt extrudable pharmaceutical formulation 24 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hysingla Er's drug page


5. Oxycontin

Oxycontin is protected by 32 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8894987 Tamper resistant dosage forms 29 Mar, 2030
(5 years from now)
Active
US11304908 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US11304909 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US11964056 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US8808741 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US8894988 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492389 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492391 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492392 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9492393 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9763933 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9770416 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US9775808 Tamper resistant dosage forms 24 Aug, 2027
(2 years from now)
Active
US7776314 Abuse-proofed dosage system 19 Apr, 2025
(4 months from now)
Active
US10407434 Process for preparing oxycodone compositions 30 Mar, 2025
(4 months from now)
Active
US10696684 Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US12060361 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US7674799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US7674800 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US7683072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US9073933 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US9522919 Oxycodone compositions 30 Mar, 2025
(4 months from now)
Active
US8114383 Abuse-proofed dosage form 10 Oct, 2024
(a month ago)
Expired
US10130591 Abuse-proofed dosage form 20 Nov, 2023
(1 year, 2 days ago)
Expired
US10675278 Crush resistant delayed-release dosage forms 20 Nov, 2023
(1 year, 2 days ago)
Expired
US8309060 Abuse-proofed dosage form 20 Nov, 2023
(1 year, 2 days ago)
Expired
US10369109 Abuse-proofed dosage form 16 Jun, 2023
(1 year, 5 months ago)
Expired
US9675610 Abuse-proofed dosage form 16 Jun, 2023
(1 year, 5 months ago)
Expired
US8337888 Pharmaceutical formulation containing gelling agent 06 Aug, 2022
(2 years ago)
Expired
US9060976 Pharmaceutical formulation containing gelling agent 06 Aug, 2022
(2 years ago)
Expired
US6488963 Hot-melt extrudable pharmaceutical formulation 24 Jun, 2017
(7 years ago)
Expired
US5508042 Controlled release oxycodone compositions 16 Apr, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxycontin's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Palladone

Palladone is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020
(4 years ago)
Expired
US5958452 Extruded orally administrable opioid formulations 04 Nov, 2014
(10 years ago)
Expired
US5965161 Extruded multi-particulates 04 Nov, 2014
(10 years ago)
Expired
US6335033 Melt-extrusion multiparticulates 04 Nov, 2014
(10 years ago)
Expired
US6706281 Melt-extrusion multiparticulates 04 Nov, 2014
(10 years ago)
Expired
US6743442 Melt-extruded orally administrable opioid formulations 04 Nov, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Palladone's drug page


7. Targiniq

Targiniq is protected by 24 patents, out of which 19 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7674799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US7674800 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US7683072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US9073933 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone 30 Mar, 2025
(4 months from now)
Active
US9522919 Oxycodone compositions 30 Mar, 2025
(4 months from now)
Active
US8846090 Matrix for sustained, invariant and independent release of active compounds 04 Apr, 2023
(1 year, 7 months ago)
Expired
US8846091 Matrix for sustained, invariant and independent release of active compounds 04 Apr, 2023
(1 year, 7 months ago)
Expired
US9555000 Pharmaceutical preparation containing oxycodone and naloxone 04 Apr, 2023
(1 year, 7 months ago)
Expired
US9907793 Pharmaceutical preparation containing oxycodone and naloxone 04 Apr, 2023
(1 year, 7 months ago)
Expired
US8969369 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9056051 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9084729 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9161937 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9168252 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9283216 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9283221 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9345701 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US9511066 Abuse-resistant controlled-release opioid dosage form 10 May, 2022
(2 years ago)
Expired
US6277384 Opioid agonist/antagonist combinations 22 Dec, 2018
(5 years ago)
Expired
US6696066 Opioid agonist/antagonist combinations 22 Dec, 2018
(5 years ago)
Expired
US8673355 Opioid agonist/antagonist combinations 22 Dec, 2018
(5 years ago)
Expired
US8822487 Opioid agonist/opioid antagonist/acetaminophen combinations 22 Dec, 2018
(5 years ago)
Expired
US9205082 Opioid agonist/antagonist combinations 22 Dec, 2018
(5 years ago)
Expired
US9474750 Opioid agonist/opioid antagonist/acetaminophen combinations 22 Dec, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Targiniq's drug page


8. Zurnai (autoinjector)

Zurnai (autoinjector) is protected by 21 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11857547 Compositions and methods for opioid antagonist delivery 05 Nov, 2039
(14 years from now)
Active
US11865112 Compositions and methods for opioid antagonist delivery 05 Nov, 2039
(14 years from now)
Active
US11191908 Syringe shock absorber for use in an injection device 18 Oct, 2035
(10 years from now)
Active
US11813435 Needle assisted injection device having reduced trigger force 25 Feb, 2035
(10 years from now)
Active
US10881798 Needle assisted injection device having reduced trigger force 11 Feb, 2034
(9 years from now)
Active
US11185642 Injection device with cammed ram assembly 28 Aug, 2031
(6 years from now)
Active
US10357609 Needle assisted jet injection device having reduced trigger force 21 Aug, 2031
(6 years from now)
Active
US10905827 Injection device with cammed ram assembly 21 Aug, 2031
(6 years from now)
Active
US11446440 Needle assisted injection device having reduced trigger force 21 Aug, 2031
(6 years from now)
Active
US8496619 Injection device with cammed ram assembly 21 Aug, 2031
(6 years from now)
Active
US9364610 Injection device with cammed ram assembly 21 Aug, 2031
(6 years from now)
Active
US9364611 Needle assisted jet injection device having reduced trigger force 21 Aug, 2031
(6 years from now)
Active
US9446195 Injection device with cammed ram assembly 21 Aug, 2031
(6 years from now)
Active
US10279131 Injection device with cammed RAM assembly 31 Jul, 2031
(6 years from now)
Active
US8021335 Prefilled syringe jet injector 04 Oct, 2026
(1 year, 10 months from now)
Active
US10478560 Prefilled syringe injector 24 Jan, 2026
(1 year, 2 months from now)
Active
US11446441 Prefilled syringe injector 24 Jan, 2026
(1 year, 2 months from now)
Active
US8562564 Prefilled syringe jet injector 24 Jan, 2026
(1 year, 2 months from now)
Active
US9180259 Prefilled syringe jet injector 24 Jan, 2026
(1 year, 2 months from now)
Active
US9533102 Prefilled syringe jet injector 24 Jan, 2026
(1 year, 2 months from now)
Active
US9629959 Prefilled syringe jet injector 24 Jan, 2026
(1 year, 2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurnai (autoinjector)'s drug page